Erenumab in chronic migraine: Experience from a UK tertiary centre and comparison with other real‐world evidence

Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy

(2020) Raffaele Ornello et al.   JOURNAL OF HEADACHE AND PAIN

Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study

(2020) Bianca Raffaelli et al.   Frontiers in Neurology

Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?

(2020) David Moreno-Ajona et al.   CURRENT OPINION IN NEUROLOGY

A prospective real-world analysis of erenumab in refractory chronic migraine

(2020) Giorgio Lambru et al.   JOURNAL OF HEADACHE AND PAIN

Erenumab in highly therapy-refractory migraine patients: First German real-world evidence

(2020) Armin Scheffler et al.   JOURNAL OF HEADACHE AND PAIN

Real‐World Patient Experience With Erenumab for the Preventive Treatment of Migraine

(2020) Jennifer Robblee et al.   HEADACHE

One year experience with erenumab: real-life data in 30 consecutive patients

(2020) Angelo Ranieri et al.   NEUROLOGICAL SCIENCES

Erenumab in chronic migraine with medication overuse

(2019) Stewart J. Tepper et al.   NEUROLOGY

Current and emerging evidence-based treatment options in chronic migraine: a narrative review

(2019) Elio Clemente Agostoni et al.   JOURNAL OF HEADACHE AND PAIN

Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study

(2018) Messoud Ashina et al.   CEPHALALGIA

ARISE: A Phase 3 randomized trial of erenumab for episodic migraine

(2018) David W Dodick et al.   CEPHALALGIA

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

(2018)   CEPHALALGIA

Monoclonal antibodies for migraine: an update

(2018) Daniel Castle et al.   JOURNAL OF NEUROLOGY

Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study

(2018) Uwe Reuter et al.   LANCET

Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial

(2017) Stewart Tepper et al.   LANCET NEUROLOGY

A Controlled Trial of Erenumab for Episodic Migraine

(2017) Peter J. Goadsby et al.   NEW ENGLAND JOURNAL OF MEDICINE

Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study

(2016) David W. Dodick et al.   HEADACHE

Adherence to oral migraine-preventive medications among patients with chronic migraine

(2014) Zsolt Hepp et al.   CEPHALALGIA

A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study

(2013) Lars J Stovner et al.   CEPHALALGIA

Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS)

(2010) AM Blumenfeld et al.   CEPHALALGIA

Chronic Migraine: Epidemiology and Disease Burden

(2010) Aubrey N. Manack et al.   Current Pain and Headache Reports

OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program

(2010) David W. Dodick et al.   HEADACHE

CGRP and its receptors provide new insights into migraine pathophysiology

(2010) Tony W. Ho et al.   Nature Reviews Neurology